Cumulative cenobamate prescriptions exceed 300,000 patients

SK Biopharm said on November 18 that it had attended the Jefferies Global Healthcare Conference and presented its mid- to long-term growth strategy, built on the continued growth of its epilepsy drug cenobamate and the expansion of its new pipeline.

Lee Donghoon, CEO of SK Biopharmaceuticals, is presenting at the Jefferies Global Healthcare Conference. SK Biopharmaceuticals

Lee Donghoon, CEO of SK Biopharmaceuticals, is presenting at the Jefferies Global Healthcare Conference. SK Biopharmaceuticals

View original image

The Jefferies Global Healthcare Conference, the largest healthcare conference in Europe, was held in London, the United Kingdom, from November 16 to 19 (local time) this year. SK Biopharm attended for the fourth consecutive year and was the only Korean pharmaceutical or biotech company to give an in-person presentation.


At an in-person presentation on November 17, SK Biopharm CEO Lee Donghoon disclosed that the cumulative number of patients worldwide prescribed cenobamate had exceeded 300,000 as of September this year. SK Biopharm is expanding the drug's indications, age range, and formulations. In addition to its existing indication for partial-onset seizures in adults, the company is pursuing expanded indications for primary generalized tonic-clonic (PGTC) seizures in patients aged 12 and older and for partial-onset seizures in children. It is also seeking approval for an oral suspension for patients who have difficulty swallowing pills.


SK Biopharm has secured a second product in the central nervous system (CNS) field. In August, the company signed an agreement with Biohaven to acquire opacalim, a candidate epilepsy drug. A Phase 2/3 trial is underway in adults with partial-onset seizures, and topline results from the RISE3 trial, which has completed patient enrollment, are expected to be announced by the end of this year. In oncology, the company is identifying new therapeutic targets, focusing on next-generation technologies such as radiopharmaceutical therapies and targeted protein degradation.


Lee also introduced the company's "AI-native operations" strategy, which applies artificial intelligence (AI) across drug development and company operations, and its "East-West Bridge" strategy, which identifies early-stage candidates from Asian biotech companies and connects them with global markets.



"Through the U.S. commercialization of cenobamate, SK Biopharm has demonstrated its ability to develop a new drug itself and grow it in global markets," Lee said. "We will leverage AI and open innovation to accelerate drug development and strengthen our competitiveness, while expanding our business model to connect promising assets from Asia with global markets and reinforce the foundation for sustainable growth."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing